https://medlineplus.gov/druginfo/meds/a625087.html
Sebetralstat: MedlinePlus Drug Information
Sebetralstat: learn about side effects, dosage, special precautions, and more on MedlinePlus
sebetralstatmedlineplusdruginformation
https://www.tga.gov.au/resources/auspmd/ekterly-sebetralstat
Ekterly (sebetralstat) | Therapeutic Goods Administration (TGA)
Mar 20, 2026 - Ekterly (sebetralstat) has been approved for hereditary angioedema (HAE) attacks caused by C1 inhibitor deficiency or dysfunction, in patients aged 12 years...
ekterlysebetralstattherapeuticgoodsadministration
https://www.tga.gov.au/resources/designations-determinations/notice-sebetralstat-jace-pharma-pty-ltd
Notice for sebetralstat (JACE Pharma Pty Ltd) | Therapeutic Goods Administration (TGA)
pty ltdnoticesebetralstatjacepharma
https://www.biospace.com/press-releases/kalvista-pharmaceuticals-announces-fda-will-not-meet-pdufa-goal-date-for-sebetralstat-nda-for-hereditary-angioedema-due-to-fda-resource-constraints
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for...
https://www.tga.gov.au/resources/artg/462847
EKTERLY sebetralstat 300 mg film coated tablets blister pack (462847) | Therapeutic Goods...
Dec 11, 2025 - Australian Register of Therapeutic Goods (ARTG) information for EKTERLY sebetralstat 300 mg film coated tablets blister pack.
300 mgfilm coated
https://www.businesswire.com/news/home/20240213650216/en/KalVista-Pharmaceuticals-Reports-Phase-3-KONFIDENT-Trial-Meets-All-Endpoints-for-Sebetralstat-as-First-Oral-On-demand-Therapy-for-Hereditary-Angioedema
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small ...
https://www.businesswire.com/news/home/20240618507569/en/KalVista-Submits-New-Drug-Application-to-FDA-for-Sebetralstat-as-First-Oral-On-demand-Treatment-for-Hereditary-Angioedema
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) rev...
https://www.goodrx.com/ekterly/what-is
Ekterly (sebetralstat): Uses, Side Effects, Dosage & Reviews
Learn about Ekterly (sebetralstat) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.
side effectsekterlysebetralstatusesdosage